Purpose From 2002 to 2007, the International Berlin-Frankfurt-Münster Study Group
conducted a prospective randomized clinical trial (ALL IC-BFM 2002) for the management of …

A fully-standardized EuroFlow 8–color antibody panel and laboratory procedure was stepwise
designed to measure minimal residual disease (MRD) in B-cell precursor (BCP) acute …

Introduction Since the beginning of COVID-19 pandemic, it is known that the severe course
of the disease occurs mostly among the elderly, whereas it is rare among children and young …

Mixed phenotype acute leukaemia (MPAL) is a high-risk subtype of leukaemia with myeloid
and lymphoid features, limited genetic characterization, and a lack of consensus regarding …

Background Previous studies have shown that children and adolescents with COVID-19
generally have mild disease. Children and adolescents with cancer, however, can have severe …

Importance Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with
efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). …

Flow cytometric immunophenotyping has become essential for accurate diagnosis,
classification, and disease monitoring in hemato‐oncology. The EuroFlow Consortium has …

Immunophenotyping by flow cytometry (FCM) is a worldwide mainstay in leukemia
diagnostics. For concordant multicentric application, however, a gap exists between available …

Purpose Monitoring of residual disease (RD) by flow cytometry in childhood acute myeloid
leukemia (AML) may predict outcome. However, the optimal time points for investigation, the …

Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood. Despite
enormous improvement of prognosis during the last half century, ALL remains a major cause …